Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 6:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Antiretroviral Treatment Interruption Clear all
Completed No phase listed Observational

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

NCT00238459
View directory record Official record
Conditions
HIV Infections
Interventions
Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 26, 2026, 6:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

CAR-T Cells for HIV Infection

NCT04648046
View directory record Official record
Conditions
HIV Infections
Interventions
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Drug · Biological · Other
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 2 Interventional Results available

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

NCT00071890
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin 2, HAART, Treatment interruption
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 26, 2026, 6:02 PM EDT
Completed No phase listed Observational

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

NCT00016783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2013 · Synced Sep 26, 2026, 6:02 PM EDT
Withdrawn Phase 3 Interventional

Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment

NCT00011128
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 1 Interventional

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

NCT05245292
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117-LS, 10-1074-LS, N803
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 1 Interventional

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

NCT00842634
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
ZFN modified T cells, Structured Treatment Interruption
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 26, 2026, 6:02 PM EDT
Recruiting Phase 2 Interventional

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

NCT05419024
View directory record Official record
Conditions
HIV
Interventions
Acute Treatment Interruption
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NCT00038259
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 3 Interventional

Intermittent vs. Continuous HAART to Treat Chronic HIV Infection

NCT00025909
View directory record Official record
Conditions
HIV Infection
Interventions
Leukapheresis
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Antiretroviral Activity of 3BNC117

NCT02588586
View directory record Official record
Conditions
HIV-1 Infection
Interventions
3BNC117, Antiretroviral Treatment Interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 26, 2026, 6:02 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Mapping the Human HIV Chronobiome

NCT03133559
View directory record Official record
Conditions
Hiv, Healthy
Interventions
Observational
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Baricitinib Curative Repression of HIV-1

NCT07209267
View directory record Official record
Conditions
HIV Infection, HIV
Interventions
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

NCT01044654
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
SB-728-T
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 1 Interventional

3BNC117 and 10-1074 in HIV-infected Individuals

NCT02825797
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
3BNC117, 10-1074, Analytical treatment interruption, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 26, 2026, 6:02 PM EDT
Not yet recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

NCT06987318
View directory record Official record
Conditions
HIV-1-infection
Interventions
VRC07-523LS, PGT121.414.LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

NCT01335191
View directory record Official record
Conditions
HIV Infections
Interventions
TUTI-16 (1.0 mg), Placebo
Biological · Other
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Enhancement by Poly-ICLC During HIV-1 Infection

NCT02071095
View directory record Official record
Conditions
HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions
Arm A: Poly-ICLC, Arm B: Normal Saline
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 26, 2026, 6:02 PM EDT
Recruiting Phase 1 Interventional

A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

NCT07569029
View directory record Official record
Conditions
HIV
Interventions
DV700P-RNA 100 mcg, DV701B1.1-RNA 100 mcg
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

NCT00414518
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 26, 2026, 6:02 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Fostemsavir (FTR), SOC INSTI-based ART
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Bakersfield, California • San Diego, California • Ft. Pierce, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 26, 2026, 6:02 PM EDT
Completed No phase listed Observational

Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy

NCT00001899
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 26, 2026, 6:02 PM EDT
Completed Not applicable Interventional

Effect of Interleukin-2 on HIV Treatment Interruption

NCT00015704
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 6:02 PM EDT